Cellares signed a long‑term lease for a Smart Factory at Leiden Bio Science Park to serve as its European headquarters and expand automated cell‑therapy manufacturing capacity. The facility will host Cellares’ Cell Shuttle and Cell Q platforms and is slated for phased fit‑out and occupancy in 2026 to support regional clinical and commercial supply. Separately, Agenus closed a $141 million strategic collaboration with Zydus that transfers U.S. biologics manufacturing sites and secures dedicated capacity for its BOT+BAL immunotherapy program. The arrangement provides Agenus with manufacturing stability and capital to advance its Phase III program while Zydus establishes a U.S.-based CDMO footprint.